New PrecisA Monoclonals for analysis of brain and neuroendocrine tumors
We continuously expand our portfolio of cancer research related products. Our latest set of mouse monoclonals focuses on markers for glioma and neuroendocrine tumors.
Gliomas are brain tumors that start in glial cells. These are the supporting cells of the brain and the spinal cord. Gliomas are classified according to the type of glial cell involved in the tumor, as well as the tumor's genetic features, which can help predict how the tumor will behave over time and the treatments most likely to work. Among the new additions are antibodies targeting PTEN, NF1, EZH2 and ID1.
Atlas Antibodies now offers 100 PrecisA Monoclonals™ and over 1,350 Triple A Polyclonals™ for glioma research.
Neuroendocrine tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the lungs, appendix, small intestine, rectum and pancreas. New products include Anti-RIPK1, Anti-CHGB, Anti-HMOX1 and Anti-INSM1.
Our monoclonals are validated for use in IHC, ICC-IF and Western Blot.